The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf) in Advanced Patients Harboring the V600 BRAF Mutation

Trial Profile

The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf) in Advanced Patients Harboring the V600 BRAF Mutation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2015

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Colorectal cancer; Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 May 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 12 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top